R. Rampling

TL;DR: Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 months in the PCB group, and freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received.

TL;DR: This study demonstrates the feasibility of using replication-competent HSV in human therapy by evaluating the safety of 1716 in patients with relapsed malignant glioma and finding no induction of encephalitis, no adverse clinical symptoms, and no reactivation of latent HSV.

TL;DR: Temozolomide demonstrated modest clinical efficacy, with an acceptable safety profile and measurable improvement in quality of life in patients with recurrent GBM, and should be explored further in an adjuvant setting and in combination with other agents.

TL;DR: All six of the brain tumors investigated could metabolize tirapazamine to the two-electron reduction product, favor primary brain tumors as suitable targets for bioreductive therapy.

TL;DR: Patients who develop spinal metastases are at risk of irreversible spinal cord damage and the only accurate investigation to establish the presence and site of a compressive lesion is magnetic resonance imaging (MRI).